Shire plc (ADR) (NASDAQ:SHPG)

CAPS Rating: 4 out of 5

A pharmaceutical company that focuses on meeting the needs of the specialist physician.

Results 1 - 20 of 23 : 1 2 Next »

Recs

0
Member Avatar ehensim1 (99.47) Submitted: 4/19/2014 1:30:42 PM : Outperform Start Price: $144.32 SHPG Score: +0.92

Monopoly on the ADHD drugs until the Vyvanse patents expire or something better comes out before then.

Recs

0
Member Avatar pchop123 (78.31) Submitted: 4/7/2014 10:29:22 AM : Outperform Start Price: $144.32 SHPG Score: +0.92

great buy-in point

Recs

0
Member Avatar TMFCandyMountain (99.75) Submitted: 11/19/2013 2:25:44 PM : Outperform Start Price: $144.32 SHPG Score: +0.92

I like their focus on rare diseases. That sets them apart from the competition.

Recs

0
Member Avatar line70day (27.48) Submitted: 10/31/2013 2:39:55 PM : Outperform Start Price: $144.32 SHPG Score: +0.92

SHPG growth rate yr over yr 26.67%
1 yr growth rate 9.80% eps -13.80% div 0.53
trailing 12Q rev 3.67 B eps 3.28 ytd div 0.53
1yr change +55.22%
net change in cash & cash equivalents 862.20

Recs

0
Member Avatar leglamp (58.10) Submitted: 6/20/2012 1:50:11 PM : Outperform Start Price: $90.90 SHPG Score: +24.54

Continuing gastro and ADD/ADHD pipeline

Recs

0
Member Avatar Lcrazylegs84 (< 20) Submitted: 10/1/2011 12:48:30 AM : Outperform Start Price: $90.82 SHPG Score: -3.45

Overall a great company

Recs

0
Member Avatar btthus (< 20) Submitted: 8/16/2011 4:45:20 PM : Outperform Start Price: $97.26 SHPG Score: -3.50

Investors.com 99 Composite Rating

Recs

0
Member Avatar JDAR5715 (< 20) Submitted: 1/10/2011 7:32:11 PM : Outperform Start Price: $75.21 SHPG Score: +49.67

Going to be bought by a large company

Recs

0
Member Avatar cashman79 (66.32) Submitted: 9/15/2010 9:55:36 AM : Outperform Start Price: $69.19 SHPG Score: +47.14

watch

Recs

0
Member Avatar CuriousDonkey (47.54) Submitted: 7/6/2010 3:57:40 PM : Outperform Start Price: $61.94 SHPG Score: +56.72

As Genzyme continues to suffer with FDA and EU concerns, Shire is swooping in and displacing a captive market. This company is amping up a significant manufacturing base and jumping at the opportunity to gill Genzyme's market.

Recs

0
Member Avatar reachnvj (< 20) Submitted: 1/6/2010 2:15:22 PM : Outperform Start Price: $57.49 SHPG Score: +92.44

If they get the nod from FDA, this stock will take-off. With GENZ dealing with manufacturing issues, SHPGY can take on some market share with their new drug in the same category.

Recs

0
Member Avatar sunsluv72 (82.79) Submitted: 11/14/2009 6:20:13 PM : Outperform Start Price: $57.18 SHPG Score: +88.85

This stock should out perform in the next few months due the shut down and production stop forced by the FDA on Genezyme and Shire is the only other manufacture that is getting back flow to fill orders.

Recs

0
Member Avatar TMFBiologyFool (98.65) Submitted: 6/5/2009 7:21:32 PM : Underperform Start Price: $40.23 SHPG Score: -165.57

Still looks overpriced. Trying to get patients to switch to Vyvanse will be difficult with generic Adderall available.

Recs

0
Member Avatar BigBomber (29.65) Submitted: 4/24/2009 10:58:41 AM : Outperform Start Price: $37.58 SHPG Score: +174.00

Speciality

Recs

1
Member Avatar VoodooEconomist (36.30) Submitted: 1/5/2009 7:24:39 AM : Outperform Start Price: $43.78 SHPG Score: +131.79

Possible buyout by PFE

Recs

1
Member Avatar Iznogoud888 (59.79) Submitted: 3/25/2008 2:48:42 PM : Outperform Start Price: $59.85 SHPG Score: +103.24

A rise in Vyvanse market share will drive the value up. Potential takeover.

Recs

0
Member Avatar donhaupt1 (82.51) Submitted: 2/9/2008 3:16:32 PM : Outperform Start Price: $51.41 SHPG Score: +140.68

Vyvanse, their new drug for ADHD, will likely get an Adult indication from the FDA within 4-6 months, and its 12 hour duration on one pill a day is a real improvement in this area

Recs

0
Member Avatar JjcampNR (71.22) Submitted: 12/11/2007 12:28:44 AM : Outperform Start Price: $70.06 SHPG Score: +81.98

New longer lasting ADD/ADHD drug (Vyvanse) with FDA approval entering the market. While Adderall may be generic soon, Vyvanse is a once per day dosing as apposed to typically twice per day with Adderall XR.

Also, Shire's HGT (Human Genetic Therapy) division is the exclusive supplier of therapies for some genetic conditions (such as Hunter's Syndrome). Pipeline seems to be undervalued as well.

Recs

0
Member Avatar JCash22 (95.62) Submitted: 12/10/2007 7:39:53 PM : Underperform Start Price: $70.06 SHPG Score: -81.98

more than fair value. will normalize soon.

Recs

0
Member Avatar tharlow (64.51) Submitted: 9/4/2007 7:42:29 PM : Outperform Start Price: $75.94 SHPG Score: +61.65

Easy double on massive near-term growth. Market is slow to catch on, and this stock is grossly undervalued.

Results 1 - 20 of 23 : 1 2 Next »

Featured Broker Partners


Advertisement